•The 4th largest funded exosome startup in the world
•To help advance its exosome pharmaceutical R&D and cosmeceutical business SEOUL, South Korea, September 12, 2018-- ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment. Since it was established in January 2017, ExoCoBio has raised about $46 million accumulatively including series A round in April 2017 of $11 million.